Global Cell-Based Assays Market (2021 to 2026) - by Product
25 May 2021
Acquisition
Dublin, May 25, 2021 (GLOBE NEWSWIRE) -- The "Cell-Based Assays Market Based on Product & Service, Application, End-User, and Geography - Global Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering. The Cell-Based Assays Market is estimated to grow at the rate of 16.6% CAGR by 2026. A cell-based assay is an experiment that uses live cells. The basic methods include different assays that can be used in computing cell toxicity, growth, motility, and the production of a particular cellular product and cellular morphology. Cell-based assays offer the nearest depiction of the real-life model as it employs live cells in experimentation.
The factors accelerating the cell-based assays market are the increasing elderly population and the increasing occurrence of chronic diseases, including cancer, diabetes, and epilepsy. Additionally, the significantly increasing drug discovery is anticipated to escalate the demand for cell-based assays since it is majorly used in examining the efficiency of drugs. Several companies are involved in the drug discovery, which requires cell-based assay for reviewing the new drugs, which are expected to boost the cell-based assays market in the prevailing years. Simultaneously, the restraining factors of the market include the high costs of the assays and lack of skilled labor in this field.Cell-Based Assays Market based on Product & Service
Cell-Based Assays Market based on Application
Cell-Based Assays Market based on End-User
Cell-Based Assays Market based on Geography
The market is based on products & services, and this segment is further segmented into consumables, instruments, and services. The consumables segment is likely to hold the highest share in the market. The highest share is majorly ascribed to the increasing usage and requirement in the pre-requisite steps of cell-based assay methodologies
Based on the application of cell-based assays, the market is categorized into drug discovery, basic research, and other applications. The drug discovery segment is witnessing a significant growth rate in the market due to the increase in investments in research and developments for drug discovery by various biopharmaceutical companies and the development of drugs to treat multiple diseases.Then further based on end-users, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, and Contract Research Organizations. The pharmaceutical and biotechnology companies segment has acquired a significant share in the market growth. This is due to the increasing demand for new drugs to globally treat various diseases among the rising elderly population. Rising competition among the healthcare companies and increasing research and development activities by pharmaceutical and biotechnology companies are the major factors boosting the segment growth.In the regional market of cell-based assays, the North American region has occupied the market's substantial share. Factors including the presence of various numbers of pharmaceutical companies, drastically growing drug-based developments and research activities, and a rising number of well-established biotechnological laboratories are accelerating the region's market growth.Cell-based assays occupy various advantages over conventional biochemical assays and animal models, and these advantages have majorly driven the rising demand for these assays in the present years. There is increasing usage of cell-based assays as the preferred tool for testing potential drug compounds and toxicity testing, increasing demand from the drug development companies. The cell-based assays demand will increase further due to increased allotment of resources to drug discovery by companies, the existence of many proteins of which functions are yet to be known, and the rising demand for biological drugs.Prominent players of the market are Becton, Dickinson and Company, Charles River Laboratories, Inc., Cell Signaling Technology, Inc., Danaher Corporation, Thermo Fisher Scientific Inc., Lonza Group Ltd., Cell Biolabs, Inc., General Electric Company, Merck KGaA, Perkinelmer, Inc., Promega Corporation, Cisbio Bioassays, and Discoverx Corporation.The cell-based assays are having a prominent role in the present scenario of a rising number of diseases worldwide in the discovery and development of drugs since these cell-based assays provide enormous benefits in screening all types of compounds.
Key Topics Covered: 1. Executive Summary2. Industry Outlook2.1. Industry Overview2.2. Industry Trends3. Market Snapshot3.1. Market Definition3.2. Market Outlook3.2.1. Porter Five Forces3.3. Related Markets4. Market characteristics4.1. Market Overview4.2. Market Segmentation4.3. Market Dynamics4.3.1. Drivers4.3.2. Restraints4.3.3. Opportunities4.4. DRO - Impact Analysis5. Product & Service: Market Size & Analysis5.1. Overview5.2. Consumables5.2.1. Reagents5.2.2. Assay Kits5.2.3. Probes & Labels5.2.4. Microplates5.2.5. Cell Lines5.3. Instruments5.4. Services6. Application: Market Size & Analysis6.1. Overview6.2. Drug Discovery6.3. Basic Research6.4. Other Applications7. End User: Market Size & Analysis7.1. Overview7.2. Pharmaceutical & Biotechnology Companies7.3. Academic & Government Institutes7.4. Contract Research Organizations8. Geography: Market Size & Analysis8.1. Overview8.2. North America8.3. Europe8.4. Asia Pacific8.5. Rest of the World9. Competitive Landscape9.1. Competitor Comparison Analysis9.2. Market Developments9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships9.2.2. Product Launches and execution10. Vendor Profiles10.1. Becton, Dickinson and Company10.1.1. Overview10.1.2. Financial Overview10.1.3. Product Offerings10.1.4. Developments10.1.5. Business Strategy10.2. Charles River Laboratories, Inc.10.2.1. Overview10.2.2. Financial Overview10.2.3. Product Offerings10.2.4. Developments10.2.5. Business Strategy10.3. Cell Signaling Technology, Inc.10.3.1. Overview10.3.2. Financial Overview10.3.3. Product Offerings10.3.4. Developments10.3.5. Business Strategy10.4. Danaher Corporation10.4.1. Overview10.4.2. Financial Overview10.4.3. Product Offerings10.4.4. Developments10.4.5. Business Strategy10.5. Thermo Fisher Scientific Inc.10.5.1. Overview10.5.2. Financial Overview10.5.3. Product Offerings10.5.4. Developments10.5.5. Business Strategy10.6. Lonza Group Ltd.10.6.1. Overview10.6.2. Financial Overview10.6.3. Product Offerings10.6.4. Developments10.6.5. Business Strategy10.7. Cell Biolabs, Inc.10.7.1. Overview10.7.2. Financial Overview10.7.3. Product Offerings10.7.4. Developments10.7.5. Business Strategy10.8. General Electric Company10.8.1. Overview10.8.2. Financial Overview10.8.3. Product Offerings10.8.4. Developments10.8.5. Business Strategy10.9. Merck KGaA10.9.1. Overview10.9.2. Financial Overview10.9.3. Product Offerings10.9.4. Developments10.9.5. Business Strategy10.10. Perkinelmer, Inc.10.10.1. Overview10.10.2. Financial Overview10.10.3. Product Offerings10.10.4. Developments10.10.5. Business Strategy11. Companies to Watch11.1. Promega Corporation11.1.1. Overview11.1.2. Products & Services11.1.3. Business Strategy11.2. Cisbio Bioassays11.2.1. Overview11.2.2. Products & Services11.2.3. Business Strategy11.3. Discoverx Corporation11.3.1. Overview11.3.2. Products & Services11.3.3. Business Strategy 12. Analyst Opinion13. Annexure
For more information about this report visit
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.